Log In
Print
BCIQ
Print
Print this Print this
 

suvorexant (Belsomra) (MK-4305)

  Manage Alerts
Collapse Summary General Information
Company Merck & Co. Inc.
DescriptionDual orexin receptor antagonist
Molecular Target Orexin 1 receptor (HCRTR1) (OX1R) ; Orexin 2 receptor (HCRTR2) (OX2R)
Mechanism of ActionOrexin receptor antagonist
Therapeutic ModalitySmall molecule
Latest Stage of DevelopmentApproved
Standard IndicationInsomnia
Indication DetailsTreat insomnia
Regulatory Designation

U.S. - Undisclosed Review (Treat insomnia)

Partner


 Product Details
 Archive Items are loading loading
Get a free BioCentury trial today